Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Puma Biotechnology : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

09/07/2021 | 05:31pm EDT

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375 shares of Puma common stock to three new non-executive employees.

The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award’s vesting commencement date, September 1, 2021, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.


© Business Wire 2021
All news about PUMA BIOTECHNOLOGY, INC.
04:30pCELCUITY : Unveils Partnership for Phase 2 Trial of Combination Treatment Targeting Breast..
MT
10/06PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
09/28PUMA BIOTECHNOLOGY : Citigroup Upgrades Puma Biotechnology to Buy From Neutral, Price Targ..
MT
09/21PUMA BIOTECHNOLOGY : to Present at the Cantor Virtual Global Healthcare Conference
BU
09/20PUMA BIOTECHNOLOGY, INC.(NASDAQGS : PBYI) dropped from S&P Biotechnology Select Industry I..
CI
09/07PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
09/07PUMA BIOTECHNOLOGY : to Present at the H.C. Wainwright 23rd Annual Global Investment Confe..
BU
08/06PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
08/06PUMA BIOTECHNOLOGY : RBC Cuts PT on Puma Biotechnology to $6 From $13, Citing Nerlynx 2021..
MT
08/05PUMA BIOTECH : Q2 Earnings Snapshot
AQ
More news
Analyst Recommendations on PUMA BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 264 M - -
Net income 2021 -1,60 M - -
Net cash 2021 54,4 M - -
P/E ratio 2021 -21,8x
Yield 2021 -
Capitalization 241 M 241 M -
EV / Sales 2021 0,71x
EV / Sales 2022 0,73x
Nbr of Employees 267
Free-Float 86,6%
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 5,92 $
Average target price 8,43 $
Spread / Average Target 42,4%
EPS Revisions
Managers and Directors
Alan H. Auerbach Chairman, President, CEO & Secretary
Maximo F. Nougues Chief Financial Officer
Jay M. Moyes Lead Independent Director
Troy E. Wilson Independent Director
Adrian M. Senderowicz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PUMA BIOTECHNOLOGY, INC.-41.03%247
MODERNA, INC.220.51%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.67%47 683
SEAGEN INC.-1.81%31 426
CELLTRION, INC.-39.69%25 414